Seattle Children’s Research Institute Awarded $1.6 Million to Lead National Study on Heart Defects

New drug intervention could improve outcomes for infants with congenital conditions


The U.S. Food and Drug Administration’s Office of Orphan Products Development has awarded Seattle Children’s Research Institute a $1.6 million grant to lead a 4-year, multi-site clinical trial aimed at improving long-term health in infants born with a heart defect.

Dr. Michael Portman, director of Pediatric Cardiovascular Research at Seattle Children’s Hospital and an investigator in Seattle Children’s Research Institute’s Center for Developmental Therapeutics, will be investigating whether treating infants on cardiopulmonary bypass with thyroid hormone supplement may help them recover more quickly and with fewer side effects.

“The societal cost of congenital heart disease is huge,” Portman said. “These are children who suffer lifelong effects. If we can use a medication that’s already proven to be safe to help them recover from heart surgery then that could have a major impact on their lives.”

The trial will begin enrolling participants next month and will include patients from Seattle Children’s, Stanford University Lucille Packard Children’s Hospital and Los Angeles Children’s Hospital.

Portman previously discovered the benefit of thyroid supplementation for children on bypass in a study published in 2010 in the American Heart Association’s academic journal Circulation.

Knowing thyroid hormone levels decrease in infants and children while on cardiopulmonary bypass, Portman led a team of researchers to test the safety of thyroid hormone supplementation in infants and children after cardiac surgery to determine whether it might improve patient outcomes.

The randomized clinical trial, which included children under 2 years old, revealed that giving patients thyroid hormone was safe for all ages and improved clinical outcomes in patients under 5 months old. A second study looking specifically at patients under 5 months of age is required to modify the labeling of thyroid hormone supplement, which would impact the current standard of care.

“I anticipate this study will confirm the results of our previous research so that clinicians may begin prescribing this supplement to those patients that would benefit most,” Portman said.

Congenital heart disease occurs in approximately 32,000 infants per year and approximately 38percent of these patients will have one or more surgical procedures in their lifetime. Over the past 20 years, more and more have undergone cardiopulmonary bypass. While the surgical procedures themselves have improved, little research has been done to investigate whether medications might be beneficial to patients after surgery. Infants are especially likely to spend prolonged time on mechanical ventilation due to poor heart function after surgery and fluid build-up in the lungs.

Portman believes these effects are worsened because cardiopulmonary bypass causes an inflammatory response that suppresses normal thyroid hormone production. Still, relatively few randomized clinical trials have evaluated agents, like thyroid supplement, provided to these infants after cardiopulmonary bypass.

“Seattle Children’s is focused on using cutting-edge research to offer the best in clinical care,”

Portman said. “If this study is successful, patients will spend less time on a ventilator, less time in cardiac intensive care, and less time in hospital. They will have the chance to grow up and live longer, healthier lives.”

About Seattle Children’s

Seattle Children’s mission is to provide hope, care and cures to help every child live the healthiest and most fulfilling life possible. Together, Seattle Children’s Hospital, Research Institute and Foundation deliver superior patient care, identify new discoveries and treatments through pediatric research, and raise funds to create better futures for patients.

Ranked as one of the top five children’s hospitals in the country by U.S. News & World Report, Seattle Children’s serves as the pediatric and adolescent academic medical center for Washington, Alaska, Montana and Idaho – the largest region of any children’s hospital in the country. As one of the nation's top five pediatric research centers, Seattle Children’s Research Institute is internationally recognized for its work in neurosciences, immunology, cancer, infectious disease, injury prevention and much more. Seattle Children’s Hospital and Research Foundation works with the Seattle Children’s Guild Association, the largest all-volunteer fundraising network for any hospital in the country, to gather community support and raise funds for uncompensated care and research.

For more information, visit seattlechildrens.org or follow us on Twitter, Facebook, Instagram or on our On the Pulse blog.